AU2003277162C1 - Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof - Google Patents
Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof Download PDFInfo
- Publication number
- AU2003277162C1 AU2003277162C1 AU2003277162A AU2003277162A AU2003277162C1 AU 2003277162 C1 AU2003277162 C1 AU 2003277162C1 AU 2003277162 A AU2003277162 A AU 2003277162A AU 2003277162 A AU2003277162 A AU 2003277162A AU 2003277162 C1 AU2003277162 C1 AU 2003277162C1
- Authority
- AU
- Australia
- Prior art keywords
- group
- compound
- independently chosen
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/262,573 US20040063695A1 (en) | 2002-09-30 | 2002-09-30 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
US10/262,573 | 2002-09-30 | ||
US48025303P | 2003-06-20 | 2003-06-20 | |
US60/480,253 | 2003-06-20 | ||
PCT/US2003/031005 WO2004028480A2 (fr) | 2002-09-30 | 2003-09-30 | Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2003277162A1 AU2003277162A1 (en) | 2004-04-19 |
AU2003277162B2 AU2003277162B2 (en) | 2009-07-16 |
AU2003277162C1 true AU2003277162C1 (en) | 2009-12-24 |
Family
ID=32044981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003277162A Ceased AU2003277162C1 (en) | 2002-09-30 | 2003-09-30 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1549321A4 (fr) |
JP (1) | JP4977319B2 (fr) |
KR (1) | KR20050061501A (fr) |
CN (1) | CN100356922C (fr) |
AP (1) | AP2005003292A0 (fr) |
AU (1) | AU2003277162C1 (fr) |
BR (1) | BR0314943A (fr) |
CA (1) | CA2500498C (fr) |
EA (1) | EA009847B1 (fr) |
MX (1) | MXPA05003366A (fr) |
NZ (1) | NZ538809A (fr) |
PL (1) | PL376147A1 (fr) |
WO (1) | WO2004028480A2 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3091011T3 (en) | 2006-04-07 | 2018-02-26 | Vertex Pharma | MODULATORS OF ATP BINDING CASSETTE TRANSPORT |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8283351B2 (en) | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
WO2009038913A2 (fr) * | 2007-08-24 | 2009-03-26 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
ES2445447T3 (es) | 2007-11-16 | 2014-03-03 | Vertex Pharmaceuticals Inc. | Moduladores de isoquinolina de transportadores de casete de unión a ATP |
KR20100101130A (ko) | 2007-12-07 | 2010-09-16 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
KR20100134063A (ko) * | 2008-03-25 | 2010-12-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 낭포성 섬유증 막투과 전도성 조절자의 수용성 소분자 억제제 |
NZ616097A (en) | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
WO2009131951A2 (fr) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Composés, compositions et procédés comprenant des dérivés isoxazole |
US8207205B2 (en) | 2008-04-21 | 2012-06-26 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2010033626A1 (fr) * | 2008-09-19 | 2010-03-25 | Institute For Oneworld Health | Composés, compositions et procédés comprenant des dérivés d'imidazole et de triazole |
US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
US20120219543A1 (en) * | 2009-10-20 | 2012-08-30 | Raphael Scharfmann | Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
PL3835297T3 (pl) | 2010-03-25 | 2023-09-11 | Vertex Pharmaceuticals Incorporated | Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu |
LT3150198T (lt) | 2010-04-07 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas |
RU2579370C2 (ru) | 2010-04-07 | 2016-04-10 | Вертекс Фармасьютикалз Инкорпорейтед | Твердые формы 3-(2, 2-дифторбензо[d][1, 3] диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
SG184987A1 (en) | 2010-04-22 | 2012-11-29 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
CN103153287A (zh) | 2010-08-23 | 2013-06-12 | 弗特克斯药品有限公司 | (R)-1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)-N-(1-(2,3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用 |
CN102133402B (zh) * | 2011-03-24 | 2013-06-12 | 首都医科大学附属北京同仁医院 | 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用 |
JP6014816B2 (ja) | 2011-05-10 | 2016-10-26 | 国立大学法人神戸大学 | Ras機能阻害作用を有するチオキソチアゾリジン誘導体 |
WO2013070961A1 (fr) | 2011-11-08 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Modulateurs de transporteurs de cassette de liaison à l'atp |
RU2644723C2 (ru) | 2012-01-25 | 2018-02-13 | Вертекс Фармасьютикалз Инкорпорейтед | Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
IL283276B1 (en) | 2012-11-02 | 2024-01-01 | Vertex Pharma | Preparations containing 3-(6-(1-(2,2-difluorobenzo[1,3][D]dioxol-5-yl)cycloproponecarboxamide)-3-methylpyridin-2-yl)benzoic acid and N-(5-hydroxy- 2,4-ditert-butyl-phenyl)-4-oxo-H1-quinoline-3-carboxamide and their uses |
FR2999191B1 (fr) | 2012-12-12 | 2016-02-05 | Lesaffre & Cie | Souches probiotiques pour le traitement et/ou la prevention de la diarrhee |
PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
CN112250627B (zh) | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
CN104398509B (zh) * | 2014-11-13 | 2017-01-11 | 四川大学华西第二医院 | CFTR抑制剂CFTRinh-172在制备防治白血病细胞介导的疾病的药物中的应用 |
CN104788423B (zh) * | 2015-03-13 | 2016-10-26 | 成都理工大学 | 一种新的囊性纤维化跨膜传导调节因子抑制剂 |
EP3394083B9 (fr) | 2015-12-24 | 2022-04-27 | The Regents of the University of California | Dérivés de n-[5-[(3,4-diméthoxyphenyl)méthyl]-1,3,4-thiadiazol-2-yl]-2-méthoxy-benzeneacétamide et composés similaires en tant qu'activateurs cftr pour le traitement de constipation ou cholestasis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL96654A (en) * | 1989-12-21 | 1995-06-29 | Lilly Co Eli | Sutral derivatives containing hydroxybenzyl and sulfur-converted, and pharmaceutical preparations containing them |
AU1090795A (en) * | 1993-11-12 | 1995-05-29 | Cell Therapeutics, Inc. | Method for preventing tissue injury from hypoxia |
UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
US6423708B1 (en) * | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
CN1325309A (zh) * | 1998-08-21 | 2001-12-05 | 维洛药品公司 | 用于治疗或预防病毒感染和相关疾病的化合物、组合物和方法 |
US6484397B1 (en) * | 2000-07-11 | 2002-11-26 | Corning Incorporated | Method of assembling a catalytic converter for use in an internal combustion engine |
US20020052396A1 (en) * | 2001-04-23 | 2002-05-02 | Bailey Thomas R. | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
-
2003
- 2003-09-30 JP JP2004540305A patent/JP4977319B2/ja not_active Expired - Fee Related
- 2003-09-30 MX MXPA05003366A patent/MXPA05003366A/es active IP Right Grant
- 2003-09-30 NZ NZ538809A patent/NZ538809A/en not_active IP Right Cessation
- 2003-09-30 EP EP03798805A patent/EP1549321A4/fr not_active Withdrawn
- 2003-09-30 WO PCT/US2003/031005 patent/WO2004028480A2/fr active Application Filing
- 2003-09-30 EA EA200500583A patent/EA009847B1/ru not_active IP Right Cessation
- 2003-09-30 CN CNB038233665A patent/CN100356922C/zh not_active Expired - Fee Related
- 2003-09-30 AU AU2003277162A patent/AU2003277162C1/en not_active Ceased
- 2003-09-30 KR KR1020057005551A patent/KR20050061501A/ko active IP Right Grant
- 2003-09-30 CA CA2500498A patent/CA2500498C/fr not_active Expired - Fee Related
- 2003-09-30 BR BR0314943-9A patent/BR0314943A/pt not_active IP Right Cessation
- 2003-09-30 AP AP2005003292A patent/AP2005003292A0/xx unknown
- 2003-09-30 PL PL03376147A patent/PL376147A1/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AP2005003292A0 (en) | 2005-06-30 |
KR20050061501A (ko) | 2005-06-22 |
EP1549321A4 (fr) | 2007-05-23 |
WO2004028480A2 (fr) | 2004-04-08 |
PL376147A1 (en) | 2005-12-27 |
WO2004028480A3 (fr) | 2004-07-01 |
CA2500498C (fr) | 2012-08-21 |
BR0314943A (pt) | 2005-08-02 |
NZ538809A (en) | 2008-06-30 |
MXPA05003366A (es) | 2005-10-05 |
EP1549321A2 (fr) | 2005-07-06 |
AU2003277162B2 (en) | 2009-07-16 |
AU2003277162A1 (en) | 2004-04-19 |
CA2500498A1 (fr) | 2004-04-08 |
CN100356922C (zh) | 2007-12-26 |
EA009847B1 (ru) | 2008-04-28 |
JP2006503853A (ja) | 2006-02-02 |
CN1684686A (zh) | 2005-10-19 |
EA200500583A1 (ru) | 2005-12-29 |
JP4977319B2 (ja) | 2012-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003277162C1 (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | |
US8058295B2 (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | |
ZA200502517B (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | |
US7888332B2 (en) | Hydrazide-containing CFTR inhibitor compounds and uses thereof | |
DE69936150T2 (de) | Indomethacin-amidderivate zur antiangiogenen und/oder antitumorigen verwendung | |
KR20020015382A (ko) | 포스페이트 수송 억제제 | |
JP2011517674A (ja) | 嚢胞性線維症膜コンダクタンス制御因子の水溶性小分子阻害剤 | |
EP1937233B1 (fr) | Moduler l'equilibre du liquide intestinal en utilisant des calcimimetiques | |
AU2004263156B2 (en) | Method for treating cachexia with retinoid ligands | |
US20080027052A1 (en) | Methods for treating cystic kidney disease | |
US11382895B2 (en) | Methods for treating injury associated with exposure to an alkylating species | |
WO2000035867A1 (fr) | Nouveaux ligands d'un recepteur nucleaire | |
KR20020093983A (ko) | 포스페이트 수송 억제제 | |
DE69931814T2 (de) | Umwandlung von cox-inhibierenden, nicht cox-2 selektiven inhibitoren in derivate von cox-2 selektiven inhibitoren | |
US20220040165A1 (en) | 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine . . . . | |
JPS6056920A (ja) | 脂質レベルの低減方法 | |
KR20080111021A (ko) | 철 대사 장애의 치료를 위한 스트로빌루린의 용도 | |
JPH0578248A (ja) | 活性酸素消去剤 | |
JPH0648942A (ja) | 抗高脂血症剤及び抗動脈硬化症剤 | |
McKellar | Pharmacokinetics and Pharmacodynamics of Anti-infective and Anti-inflammatory Drugs in Animals | |
JPH01305029A (ja) | テトラゾール誘導体の使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT( S) FILED 02 JUL 2009. |
|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 JUL |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |